Optimizing Clinical Trials for Exosome & Extra-Cellular Vesicle Therapies & Scaling Manufacturing & Analytical Testing to Accelerate Regulatory Approval, Maximize Investments & De-Risk Platform Development
The exosome therapeutics field is entering a pivotal phase, with companies such as Rion and Capricor Therapeutics advancing into later-stage clinical development beyond Phase 1 and 2 trials. As the pipeline matures, rising regulatory expectations are accelerating the need to evolve exosome platforms into scalable, compliant, and commercially viable therapies. Successfully navigating this transition will require strong industry alignment across clinical strategy, manufacturing, analytics, and regulatory pathways to unlock the next wave of exosome-based therapeutics.
The 8th Exosome-Based Therapeutics Summit returns to Boston, providing a premier platform to connect with leaders in clinical development and manufacturing. Join peers to streamline your CMC strategies, advance your clinical programs, and accelerate your path toward regulatory approval and commercialization.
Attending Companies Include